In triple-negative and HER2-positive breast cancer, a high degree of tumor-infiltrating lymphocytes (TILs) is correlated with a low risk of relapse and with the effectiveness of chemotherapy [46–48]. This evidence concerns the gene ERBB2 and neoplasm.